Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pneumococcal vaccination in geriatrics].

G Wiedermann

    Fortschritte Der Medizin
    |March 29, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Pneumococcal vaccination is recommended for at-risk individuals and the elderly. This vaccine is safe, effective, and reduces fatality rates in older adults.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Use of pre-mixed insulins in diabetes treatment of young patients].

    Endokrynologia, diabetologia i choroby przemiany materii wieku rozwojowego : organ Polskiego Towarzystwa Endokrynologow Dzieciecych·2003
    Same author

    In vivo-in vitro model for the assessment of clinically relevant antimalarial cross-resistance.

    The American journal of tropical medicine and hygiene·2002
    Same author

    Molecular and immunological characterization of arginine kinase from the Indianmeal moth, Plodia interpunctella, a novel cross-reactive invertebrate pan-allergen.

    Journal of immunology (Baltimore, Md. : 1950)·2001
    Same author

    Antimalarial activity of azithromycin, artemisinin and dihydroartemisinin in fresh isolates of Plasmodium falciparum in Thailand.

    Acta tropica·2001
    Same author

    Recombinant dissection of myosin heavy chain of Toxocara canis shows strong clustering of antigenic regions.

    Parasitology research·2001
    Same author

    Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica.

    Antimicrobial agents and chemotherapy·2001
    Same journal

    [More information--less pain. Procedure in pain following amputation of limbs. Brachial plexus injury and nerve root avulsion. Interview by Susanne Kammerer].

    Fortschritte der Medizin·1999
    Same journal

    [Galenic alternatives to unstable tocopherol acetate. "Smeared" or cheated?--Vitamin E in facial ointments].

    Fortschritte der Medizin·1999
    Same journal

    [Gene diagnosis in the hand of the physician].

    Fortschritte der Medizin·1999
    Same journal

    [Is non-toxic cancer therapy through biotechnology a possibility?].

    Fortschritte der Medizin·1999
    Same journal

    [Smoking withdrawal in practice and clinic].

    Fortschritte der Medizin·1999
    Same journal

    [The future of pancreas diagnosis. An exclusive training service of the Gastro-Ligue for dermatologists].

    Fortschritte der Medizin·1999
    See all related articles

    Area of Science:

    • Immunology
    • Vaccinology
    • Public Health

    Context:

    • Pneumococcal disease poses a significant risk to specific populations, including those with chronic health conditions and the elderly.
    • Current vaccination strategies involve polysaccharide vaccines (14- or 17-valent).

    Purpose:

    • To outline the recommendations for pneumococcal vaccination based on risk factors and age.
    • To review the safety, immunogenicity, and efficacy of pneumococcal vaccines.

    Summary:

    • Pneumococcal vaccination is advised for individuals with heart/pulmonary diseases, sickle cell anemia, post-splenectomy, Hodgkin's disease, multiple myeloma, and immune suppression, as well as adults over 60.
    • Available 14- or 17-valent polysaccharide vaccines are well-tolerated with good immunogenicity in both young and elderly populations.

    Related Experiment Videos

  • Protective antibody levels are achieved, and a field trial in the elderly demonstrated a positive impact on case-fatality rates.

    • Impact:

    • Pneumococcal vaccination can reduce the severity and mortality associated with pneumococcal infections in vulnerable groups.
    • Understanding vaccination guidelines and potential side effects is crucial for healthcare providers and patients.
    • Recommendations suggest avoiding repeat vaccination within 4-5 years to prevent local reactions.